{
  "topic": {
    "stem": "SELPERCATINIB_RET_REVIEW",
    "name": "Selpercatinib in RET+ NSCLC/MTC (LIBRETTO)",
    "ncts": [
      "NCT03157128",
      "NCT04194944"
    ],
    "drug_patterns": [
      "selpercatinib"
    ],
    "condition_patterns": [
      "lung",
      "thyroid"
    ]
  },
  "trials": [
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": false,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": true,
        "E_two_arms": false,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT03157128",
        "aact_title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)",
        "aact_acronym": "LIBRETTO-001",
        "start_date": "2017-05-02",
        "primary_completion_date": "2025-02-14",
        "aact_intvs": [
          "LOXO-292"
        ],
        "aact_conditions": [
          "any solid tumor",
          "colon cancer",
          "medullary thyroid cancer",
          "non-small cell lung cancer"
        ],
        "pmid": "39983053",
        "pubmed_year": 2025,
        "pubmed_doi": "10.1200/JCO-24-02076",
        "aact_per_arm_counts": {},
        "aact_primary_outcome_measure": "Phase 1: MTD",
        "aact_outcome_count_rows": []
      }
    },
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": true,
        "E_two_arms": true,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT04194944",
        "aact_title": "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer",
        "aact_acronym": "LIBRETTO-431",
        "start_date": "2020-02-17",
        "primary_completion_date": "2023-05-01",
        "aact_intvs": [
          "Selpercatinib",
          "Carboplatin",
          "Cisplatin",
          "Pemetrexed",
          "Pembrolizumab"
        ],
        "aact_conditions": [
          "non-small cell lung cancer"
        ],
        "pmid": "38828957",
        "pubmed_year": 2024,
        "pubmed_doi": "10.1200/JCO.24.00724",
        "aact_per_arm_counts": {
          "BG000": 159,
          "BG001": 102
        },
        "aact_primary_outcome_measure": "Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)",
        "aact_outcome_count_rows": [
          [
            "OG000",
            "89.1"
          ],
          [
            "OG001",
            "84.3"
          ],
          [
            "OG000",
            "89.3"
          ],
          [
            "OG001",
            "82.4"
          ],
          [
            "OG000",
            "83.7"
          ],
          [
            "OG001",
            "65.1"
          ],
          [
            "OG000",
            "83.6"
          ],
          [
            "OG001",
            "62.7"
          ],
          [
            "OG000",
            "81.0"
          ],
          [
            "OG001",
            "57.1"
          ]
        ],
        "published_effect_type": "HR",
        "published_effect_size": 0.17,
        "published_ci_lower": 0.04,
        "published_ci_upper": 0.69,
        "published_source_snippet": "hazard ratio, 0.17 [95% CI, 0.04 to 0.69]",
        "published_extractor": "rct-extractor-v2"
      }
    }
  ],
  "gate_summary": {
    "A_aact_exists": 2,
    "C_condition_in_aact": 2,
    "D_pmid_topic_match": 2,
    "F_primary_outcome_known": 2,
    "B_drug_in_intvs": 1,
    "E_two_arms": 1
  },
  "n_total": 2,
  "n_pass_all": 1,
  "pass_rate": 0.5,
  "verdict": "VIABLE"
}